BECN1 and ovarian cancer: The loss/reduction of Beclin-1 expression has been shown to be closely related either to a better survival, as in endometrial, renal, gastric and colorectal cancers (29, 58–60), or to a reduced disease-free survival (DFS) and poorer prognosis in ovarian cancer patients receiving combined therapy with platinum and taxanes (61), and in a cohort of non-small cell lung cancer (NSCLC), in which the expression of the protein showed an independent positive prognostic factor (62).